This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 114/8/830    most recent CIRCULATIONAHA.105.577288v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, X.-S. Articles by Shohet, R. V. Search for Related Content PubMed PubMed Citation Articles by Zhao, X.-S. Articles by Shohet, R. V. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene Compound via MeSH Substance via MeSH Related Collections Apoptosis Cell signalling/signal transduction Genetically altered mice

(Circulation. 2006;114:830-837.)
© 2006 American Heart Association, Inc.

Molecular Cardiology

Endogenous Endothelin-1 Is Required for Cardiomyocyte Survival In Vivo

Xiao-Song Zhao, MD, PhD; Wentong Pan, MD; Raffi Bekeredjian, MD; Ralph V. Shohet, MD

From Internal Medicine, University of Texas Southwestern Medical Center, Dallas (X.-S.Z., W.P.); Department of Cardiology, University of Heidelberg, Heidelberg, Germany (R.B.); and Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu (R.V.S.). This study was conducted at the University of Texas Southwestern Medical Center before Drs Bekeredjian and Shohet moved to their present addresses.

Correspondence to Ralph V. Shohet, Department of Medicine, BSB 211D, 651 Ilalo St, Honolulu, HI 96813. E-mail shohet{at}hawaii.edu

Received September 20, 2005; revision received June 12, 2006; accepted June 22, 2006.

Background— Endothelin-1 (ET-1) has potent vasoconstrictor and hypertrophic actions. Pharmacological antagonists of endothelin receptors attenuate cardiac hypertrophy, have been approved for treatment of pulmonary hypertension, and are under investigation for treatment of heart failure. To investigate the role of ET-1 in the heart, we created mice with cardiomyocyte deletion of ET-1.

Methods and Results— Mice with cardiomyocyte-specific deletion of ET-1 are phenotypically normal when young. Remarkably, as the mice age or when young animals are subjected to aortic banding, they develop an unexpected phenotype of progressive systolic dysfunction and cardiac dilation. Echocardiography, necropsy, histology, and molecular phenotype confirm a dilated cardiomyopathy. Terminal deoxynucleotidyl transferase–mediated dUTP nick-end-labeling analysis reveals greater abundance of apoptotic nuclei in the ET-1–deficient hearts. Transcriptional and Western analyses suggest enhanced tumor necrosis factor (TNF)–mediated apoptosis with increases in caspase-8 activity. These ET-1–deficient hearts also have diminished nuclear factor (NF)-B activity, resulting in diminution of downstream inhibitors of TNF signaling.

Conclusions— Local ET-1 gene expression is necessary to maintain normal cardiac function and cardiomyocyte survival in mice with both age and hemodynamic stress. This cardiac-protective effect is mediated by paracrine ET-1 modulation of TNF-related apoptosis, in part through upregulation of NF-B signaling.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				J. A Drezner and K. Khan Sudden cardiac death in young athletes BMJ, July 3, 2008; 337(jul03_2): a309 - a309. [Full Text]

				C.-C. Juan, T.-Y. Chuang, C.-C. Lien, Y.-J. Lin, S.-W. Huang, C. F. Kwok, and L.-T. Ho Leptin increases endothelin type A receptor levels in vascular smooth muscle cells Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E481 - E487. [Abstract] [Full Text] [PDF]

				M. Kang, K. Y. Chung, and J. W. Walker G-Protein Coupled Receptor Signaling in Myocardium: Not for the Faint of Heart Physiology, June 1, 2007; 22(3): 174 - 184. [Abstract] [Full Text] [PDF]